Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman
May 23, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of...
Enlivex to Present at the H.C. Wainwright Global Investment Conference
May 19, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased...
Enlivex Announces Upcoming May Conference Presentations
May 10, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that...
Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting
May 09, 2022 09:05 ET
|
Enlivex Therapeutics Ltd
Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting CTLA4 and PD1 are FDA-approved as a...
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
May 05, 2022 08:37 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
Enlivex Announces Upcoming Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 02, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
Enlivex Announces Full Year 2021 Financial Results, Completion of Development of Frozen Formulation Allocetra™ Ahead of Schedule, and Provides Strategic & Business Updates
April 29, 2022 08:41 ET
|
Enlivex Therapeutics Ltd
Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in Q1 2022, twelve months ahead of schedule...
Enlivex Announces Issuance of Israeli Patent Covering Allocetra Derived from Pooled Donor Cells
March 08, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Nes-Ziona, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the...
Enlivex Strengthens Management Team with the Appointment of Biotech Industry Veteran Einat Galamidi, M.D., as Vice President, Medical
February 22, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
Dr. Galamidi joins Enlivex after 10 years at Gamida Cell Ltd., where she most recently served as Vice President of Clinical Development At Gamida Cell, Dr. Galamidi led clinical development for...
Enlivex to Detail the Application of its Innovative Macrophage Reprogramming Cell Therapy to Unmet Needs in Oncology at the 11th Annual LifeSci Partners Corporate Access Event
January 03, 2022 08:00 ET
|
Enlivex Therapeutics Ltd
** Management to participate in a panel discussion: “Innovative Approaches to Cell Therapy for Oncology,” which is taking place on Friday, January 7th, at 8:30 AM ET ** ** Panelists to discuss how...